NASDAQ
DYAI

Dyadic International Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Dyadic International Inc Stock Price

Vitals

Today's Low:
$1.8138
Today's High:
$1.85
Open Price:
$1.85
52W Low:
$1.12
52W High:
$3.56
Prev. Close:
$1.82
Volume:
5326

Company Statistics

Market Cap.:
$67.71 million
Book Value:
0.375
Revenue TTM:
$3.26 million
Operating Margin TTM:
-288.36%
Gross Profit TTM:
$807110
Profit Margin:
-251.54%
Return on Assets TTM:
-37.49%
Return on Equity TTM:
-60.3%

Company Profile

Dyadic International Inc had its IPO on 2004-11-05 under the ticker symbol DYAI.

The company operates in the Healthcare sector and Biotechnology industry. Dyadic International Inc has a staff strength of 0 employees.

Stock update

Shares of Dyadic International Inc opened at $1.85 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.81 - $1.85, and closed at $1.82.

This is a 0% increase from the previous day's closing price.

A total volume of 5,326 shares were traded at the close of the day’s session.

In the last one week, shares of Dyadic International Inc have slipped by -5.21%.

Dyadic International Inc's Key Ratios

Dyadic International Inc has a market cap of $67.71 million, indicating a price to book ratio of 2.8763 and a price to sales ratio of 14.1681.

In the last 12-months Dyadic International Inc’s revenue was $3.26 million with a gross profit of $807110 and an EBITDA of $0. The EBITDA ratio measures Dyadic International Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Dyadic International Inc’s operating margin was -288.36% while its return on assets stood at -37.49% with a return of equity of -60.3%.

In Q1, Dyadic International Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 50.8%.

Dyadic International Inc’s PE and PEG Ratio

Forward PE
11.5473
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-0.29 per share while it has a forward price to earnings multiple of 11.5473 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Dyadic International Inc’s profitability.

Dyadic International Inc stock is trading at a EV to sales ratio of 8.8301 and a EV to EBITDA ratio of -1.8247. Its price to sales ratio in the trailing 12-months stood at 14.1681.

Dyadic International Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$12.81 million
Total Liabilities
$1.88 million
Operating Cash Flow
$2.77 million
Capital Expenditure
$0
Dividend Payout Ratio
0%

Dyadic International Inc ended 2024 with $12.81 million in total assets and $0 in total liabilities. Its intangible assets were valued at $12.81 million while shareholder equity stood at $10.80 million.

Dyadic International Inc ended 2024 with $0 in deferred long-term liabilities, $1.88 million in other current liabilities, 41065.00 in common stock, $-74438304.00 in retained earnings and $0 in goodwill. Its cash balance stood at $6.37 million and cash and short-term investments were $11.74 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Dyadic International Inc’s total current assets stands at $12.81 million while long-term investments were $0.00 and short-term investments were $5.36 million. Its net receivables were $784176.00 compared to accounts payable of $770371.00 and inventory worth $0.

In 2024, Dyadic International Inc's operating cash flow was $2.77 million while its capital expenditure stood at $0.

Comparatively, Dyadic International Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$1.82
52-Week High
$3.56
52-Week Low
$1.12
Analyst Target Price
$6

Dyadic International Inc stock is currently trading at $1.82 per share. It touched a 52-week high of $3.56 and a 52-week low of $3.56. Analysts tracking the stock have a 12-month average target price of $6.

Its 50-day moving average was $1.85 and 200-day moving average was $1.72 The short ratio stood at 11.53 indicating a short percent outstanding of 0%.

Around 3029.5% of the company’s stock are held by insiders while 1612.6% are held by institutions.

Frequently Asked Questions About Dyadic International Inc

The stock symbol (also called stock or share ticker) of Dyadic International Inc is DYAI

The IPO of Dyadic International Inc took place on 2004-11-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
Tegna Inc (TGNA)
$15.92
0.53
+3.44%
$3.11
-0.13
-4.01%
HMT Limited (500191)
$35.15
-1.85
-5%
$124
-5
-3.88%
$489.65
11.45
+2.39%
$130.3
-5.2
-3.84%
$0.37
-0.01
-2.11%
$161.75
-14.85
-8.41%
$7.99
-0.38
-4.54%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. It utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus-like particles, protein antigens, ferritin nanoparticles, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to demonstrate the safety in humans of a protein produced from C1-cell protein production platform. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; and strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U., as well as co-development and marketing agreement with Fermbox Bio Inc to design, Develop, and commercialize animal free alternative proteins and biomaterials The company was founded in 1979 and is headquartered in Jupiter, Florida.

Address

140 Intracoastal Pointe Drive, Jupiter, FL, United States, 33477-5094